JOURNAL OF PRACTICAL HEPATOLOGY ›› 2015, Vol. 18 ›› Issue (5): 500-503.doi: 10.3969/j.issn.1672-5069.2015.05.013

Previous Articles     Next Articles

Efficacy and safety of umbilical cord mesenchymal stem cell transplantation in patients with autoimmune liver diseases

Lyu Shengxiang,Qiao Xiao,Liang Feng,et al.   

  1. Department of Gastroenterology,Second People’s Hospital,Huaian 223002,Jiangsu Province,China 【Abstract】 Objective To investigate the safety and efficacy of umbilical cord mesenchymal stem cell (UC-MSCs) transplantation in patients with autoimmune liver diseases(AILD). Methods The 8×107 UC-MSCs were transfused intravenously in six patients with AILD through the peripheral vein. Serum fetoprotein,interferon-γ and interleukin(IL)-4 levels were detected by ELISA. Results After the UC-MSCs therapy,the six patients achieved clinical remission with elevated albumin (ALB) [(38.85±6.98) g/L vs. (33.51±5.32) g/L,P<0.05],and decreased alanine aminotransferase [ALT,(69.95±47.96) U/L vs. (39.65±18.87) U/L)] and AST [(65.71±43.64) U/L vs.(35.52±17.24) U/L,P<0.05 for both];However,no significant changes in bilirubin,alkaline phosphatase and glutamy transpeptidase were observed after the treatment (P>0.05);There were no side effects after the treatment; The baseline serum IFN-γ and IL-4 before the treatment were (139.30~219.34) pg/ml and (29.31~55.23) pg/ml,respectively,and 24 months later,serum IFN-γ levels declined to[(116.82~167.65) pg/ml,P=0.0368] and serum IL-4 levels increased to [(43.89~69.99) pg/ml,P=0.0418]. Conclusion UC-MSCs therapy can effectively attenuate the clinical symptoms and improve the liver function in AILD patients without any severe adverse effects,and the probable mechanism may lie on the correction of immune dysfunction by UC-MSCs.
  • Received:2014-12-30 Online:2015-09-10 Published:2016-02-18

Key words: Autoimmune liver diseases, Umbilical cord mesenchymal stem cell, Efficacy